Bausch Health Companies Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
Bausch Health Companies Stock Forecast and Price Target
The average target price for Bausch Health Companies's stock set by five renowned analysts in recent months is $9.50, representing a potential upside of approximately 10.21% from its last closing price if met by 2025. This estimation is based on a high estimate of $16.00 and a low estimate of $7.00. If you are not interested in BHC stock, you may still be interested in its competitors and their current standings.
10.21% Upside
Bausch Health Companies Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Bausch Health Companies has seen a decline in its Price, from $18.35 to $0.00 – a 100.00% decrease. Next year, analysts are expecting Fair Value to reach $17.34 – an increase of 100.00%. Over the next nine years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$724.87 | Buy/Sell | $636.99 | 15.54% |
| MC Stock Forecast | LVMH Moët Hennessy - Louis Vu... | Outperform |
17
|
778.00€ | Buy/Sell | 775.72€ | 11.83% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$146.82 | Buy/Sell | $174.55 | 15.79% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$130.72 | Buy/Sell | $130.51 | 7.10% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$167.29 | Buy/Sell | $178.42 | 12.98% |
Bausch Health Companies Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Bausch Health Companies's Revenue has grown from $8.03B to $8.76B – a 9.09% increase. Next year, analysts are expecting Revenue to reach $8.89B – an increase of 1.49%. By 2030, professionals believe that Bausch Health Companies's Revenue will have decreased by 5.93%, falling to $8.24B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| OR Stock Forecast | L'Oréal | Hold |
18
|
435.75€ | Buy/Sell | 419.40€ | 3.27% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF90.00 | Buy/Sell | CHF105.00 | 19.58% |
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF218.80 | Buy/Sell | CHF307.83 | 24.54% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$106.86 | Buy/Sell | $118.92 | 18.38% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
91.62€ | Buy/Sell | 102.80€ | 18.97% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.70 | Buy/Sell | $58.15 | 21.92% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$890.68 | Buy/Sell | $961.26 | 17.89% |
| MDLZ Stock Forecast | Mondelez International | Buy |
15
|
$70.80 | Buy/Sell | $83.21 | 15.82% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£16.41 | Buy/Sell | £17.30 | 18.83% |
Bausch Health Companies EBITDA Forecast for 2023 - 2025 - 2030
Bausch Health Companies's EBITDA has decreased In the last three years, from $3.16B to $2.82B – a 10.77% drop. In the next year, analysts believe that EBITDA will reach $3.28B – an increase of 16.53%. For the next seven years, the forecast is for EBITDA to grow by 21.48%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Stock Forecast | Sun Pharmaceutical Industries | Outperform |
8
|
Rp1.52k | Buy/Sell | Rp1.52k | 4.27% |
| ALC Stock Forecast | Alcon | Outperform |
8
|
CHF71.56 | Buy/Sell | CHF90.64 | 34.66% |
| 7741 Stock Forecast | HOYA | Outperform |
5
|
¥18.31k | Buy/Sell | ¥17.66k | 14.72% |
Bausch Health Companies EBIT Forecast for 2023 - 2025 - 2030
Bausch Health Companies's EBIT has grown In the last three years, rising from $1.33B to $1.57B – a growth of 17.84%. In the next year, analysts believe that EBIT will reach $3.01B – an increase of 91.42%. For the next nine years, experts predict that Bausch Health Companies's EBIT will grow at a rate of 47.96%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| RKT Stock Forecast | Reckitt Benckiser Group | Outperform |
12
|
£43.56 | Buy/Sell | £66.68 | 23.97% |
| BEI Stock Forecast | Beiersdorf | Outperform |
17
|
139.05€ | Buy/Sell | 137.41€ | 7.16% |
| BAYN Stock Forecast | Bayer | Hold |
5
|
26.90€ | Buy/Sell | 45.15€ | 11.52% |
Bausch Health Companies EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Bausch Health Companies has seen a decline in its EPS, from $3.99 to $0.00 – a 100.00% decrease. Next year, analysts are expecting EPS to reach $3.77 – an increase of 100.00%. Over the next nine years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4452 Stock Forecast | Kao | Outperform |
18
|
¥6.41k | Buy/Sell | ¥5.95k | 0.44% |
| HOLX Stock Forecast | Hologic | Outperform |
8
|
$75.71 | Buy/Sell | $81.06 | 10.95% |
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$13.25 | Buy/Sell | $11.59 | 20.75% |
Site Navigation
.jpg)